Product
Baseline regimen of two nucleoside reverse transcriptase inhibitors
1 clinical trial
1 indication
Indication
HIV-1 InfectionClinical trial
A Phase III Multicenter, Open-Label, Randomized Study to Evaluate a Switch to MK-1439A in HIV-1-Infected Subjects Virologically Suppressed on a Regimen of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs)Status: Completed, Estimated PCD: 2018-02-22